Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image showing blood cancer clinical research and treatment review, reflecting Incyte’s tafasitamab frontMIND trial update in high-risk diffuse large B-cell lymphoma.
Pharma & Biotech

Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?

Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.

Read More
Representative image of protected laboratory workers conducting rapid molecular testing, illustrating Cepheid’s Xpert Hemorrhagic Fever panel deployment to address Ebola Bundibugyo diagnostic gaps in Africa.
Medical Devices & Diagnostics

Cepheid’s Xpert panel could reshape Ebola outbreak diagnostics, but scale is the real test

Find out how Cepheid’s Xpert Hemorrhagic Fever panel could reshape Ebola Bundibugyo testing in Africa amid urgent diagnostic gaps.

Read More
Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.
Pharma & Biotech

Merck moves Welireg earlier as FDA clears Keytruda combinations in high-risk ccRCC

Find out how Merck’s Keytruda and Welireg approval could reshape adjuvant clear cell renal cell carcinoma treatment.

Read More
Representative image: Targeted prostate cancer treatment enters focus as AstraZeneca’s Truqap approval highlights PTEN-deficient metastatic disease, biomarker testing, and the future of precision oncology.
Medical Devices & Diagnostics

Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer

Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.

Read More
Representative image of generic oncology tablets in a clinical pharmacy setting, illustrating Dr. Reddy’s Laboratories’ Bosutinib 400mg launch in the United States and its potential impact on chronic myelogenous leukemia drug access.
Pharma & Biotech

Could Dr. Reddy’s 180-day Bosutinib window change the economics of CML treatment?

Read how Dr. Reddy’s Bosutinib 400mg launch could reshape U.S. CML generics, pricing and oncology access.

Read More
Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More
Pharma & Biotech

Why Intellia’s lonvo-z Phase 3 data could raise expectations for one-time HAE treatment

Find out how Intellia’s lonvo-z Phase 3 data could change expectations for one-time hereditary angioedema treatment.

Read More
Pharma & Biotech

Why tinlarebant’s FDA submission could become a turning point in Stargardt disease treatment

Find out how Belite Bio’s tinlarebant NDA could shape the first FDA treatment path for Stargardt disease type 1.

Read More
Representative image of circular DNA analysis in a modern genetics research lab, reflecting Phinomics’ focus on explainable artificial intelligence, multi-omic cancer research and oncology biomarker discovery.
Pharma & Biotech

Could Phinomics’ circular DNA platform expose the blind spots slowing cancer drug development?

Find out how Phinomics is using circular DNA and explainable AI to reshape oncology discovery and cancer biomarker research.

Read More